Trial Profile

Prospective Observational Cohort Study to Evaluate the Benefits, Documented in the Experimental Settings, of Treatment With SGLT2-i in Normal Clinical Practice, in Subjects With Type 2 Diabetes and Older Than 70 Years.

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canagliflozin (Primary) ; Canagliflozin/metformin (Primary) ; Dapagliflozin (Primary) ; Dapagliflozin/metformin (Primary) ; Empagliflozin (Primary) ; Empagliflozin/metformin (Primary) ; Ertugliflozin (Primary) ; Ertugliflozin/metformin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms SOLDMiDiab02

01 Sep 2022 Results (n=739) assessing the effectiveness and safety of SGLT2i in the older diabetic patients in a real-life setting, published in the Pharmacological Research.
03 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com